FDA calls meeting about Eli Lilly's Alzheimer's treatment

The agency has questions about brain bleeding and swelling potentially associated with donanemab, but is generally positive about the drug. The approval decision has been postponed twice. 
Photo: Reuters/Ritzau Scanpix
Photo: Reuters/Ritzau Scanpix

The US Food and Drug Administration (FDA) is preparing to discuss its concerns about Eli Lilly’s experimental Alzheimer’s treatment donanemab ahead of an advisory committee meeting on the treatment on Monday, Endpoints reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading